Cyrus Poonawalla

Wikipedia identifies Cyrus Soli Poonawalla, born 11 May 1941 in a Pune-based Parsi family to parents Soli and Gool Poonawalla, as an Indian billionaire businessman and chairman-managing director of the Cyrus Poonawalla Group. The group includes Serum Institute of India — the world's largest vaccine manufacturer by volume — and Poonawalla Fincorp, a leading Indian NBFC.

Poonawalla founded the Serum Institute of India in 1966 and built it into the world's largest vaccine manufacturer by volume, supplying over 140 countries. Wikipedia notes the company produces more than 1.5 billion doses annually of vaccines for measles, polio and the flu. The scale of this single private company is what later enabled India to anchor the global COVID-19 vaccination response.

Poonawalla's son Adar Poonawalla is CEO of Serum Institute, having taken operational leadership of the family business. Wikipedia records that Poonawalla was married to Villoo Poonawalla, who died in 2010, and that he has two grandchildren. The succession — moving the founder's son into the CEO role while the founder remains chairman and managing director of the group — is the classic Indian family-business promoter-succession pattern.

Recognition listed by Wikipedia includes the Padma Shri in 2005 for contributions to medicine, the Padma Bhushan in 2022 for contribution in production of vaccines during COVID-19 in the field of Trade and Industry, Ernst & Young's Entrepreneur of the Year for Healthcare & Life Sciences in November 2007 and Entrepreneur of the Year for India in February 2015. The awards trace a two-decade arc that culminated with the COVID-era honor.

Wikipedia notes honorary doctorates from the University of Massachusetts Medical School in June 2018 and the University of Oxford in June 2019, the ICMR Lifetime Achievement Medal for contribution in healthcare conferred by Bill Gates in November 2019, the Lokmanya Tilak National Award in August 2021, and the Dean's Medal from the Johns Hopkins Bloomberg School of Public Health in May 2022.

In 2022, Poonawalla was ranked the 4th richest person in India on the Forbes India rich list with a net worth of $24.3 billion, and was ranked number 1 on the Hurun Global Healthcare Rich List 2022. By October 2024, Forbes listed Poonawalla and his family as the ninth-wealthiest in India with a net worth of $22.1 billion. The wealth trajectory — driven by COVID-era vaccine scale — places him as one of India's richest promoters.

Philanthropy listed by Wikipedia includes a May 2019 proposal, in partnership with Naum Koen, to supply Ukraine with 100,000 doses of measles vaccine for free vaccination during a measles outbreak. In April 2026 Poonawalla acquired Raja Ravi Varma's iconic painting 'Yashoda and Krishna' for a record Rs 167.20 crore at Saffronart's Spring Live Auction in Mumbai —.

Asian Racing Report frames Poonawalla as one of the world's richest men whose horses set him up to make an inconceivable fortune. The interview touches on his passion for breeding and racing, and what he calls the present threat to Indian racing under the Modi government's 28% betting tax on games of chance. The piece is the rare in-depth interview covering the horse-breeding origin of his vaccine business alongside his racing stewardship roles.

Poonawalla owns a pair of Bombardier Global 6500 luxury jets (range 6,500 nautical miles, top speed Mach 0.90, about 690mph), having switched from two Gulfstreams because his son Adar preferred the Global. The personal detail signals the scale of private wealth the vaccine business has produced —.

In Poonawalla's telling to Asian Racing Report, the horses came first: the horses at Poonawalla Stud Farm in the 1960s provided the raw means for him to build a business of global significance — and it did not come from racing or selling them. 'Horse serum. I went into the business of making serums and then vaccines,' he says.

Poonawalla explains the science plainly: in those days, some serums were made from horse blood worldwide. You give a vaccine to a horse — a mouse works but a larger animal yields more blood — and from the blood you process the active serum, sterilize and process it, eventually producing the final product.

Poonawalla and his younger brother Zavaray established Serums Institute of India in 1966 with starting capital of about US$25,000, growing from serums (which had limited use) into vaccines for diphtheria, tetanus, whooping cough, pneumonia, measles, and eventually the COVID vaccines Covovax and Covishield.

Poonawalla describes the COVID business windfall starkly: before COVID in 2019 he was India's 12th richest person (world rank 76th, fortune US$9.1 billion); by end-2022 he was India's fourth-richest, fortune expanded to US$21.5 billion and climbing — US$22.4 billion at the time of the interview. He frames Serum as one of the largest competitors to Pfizer and the world's biggest vaccine producer by number produced and sold.

Poonawalla explicitly positions himself as a philanthropist throughout: 'our price is low, I've been giving vaccines at 50 cents a dose and nobody could compete with this'. Serum was pre-qualified by WHO and the UK's MHRA, on which basis the company could make three billion doses of vaccine, including substantial COVID production.

Poonawalla cites recent export milestones: just that week Serum had exported six million COVID doses to Australia and three million to New Zealand, with an American-subidiary contract to supply 100 million doses to those two markets and roughly two billion doses worldwide at peak pandemic. The numbers demonstrate how a private Indian company became a top-tier global public-health supplier —.

Poonawalla tells Asian Racing Report 'the horse business in fact did help me', and he feels a reciprocal responsibility to the thoroughbred industry. He has been vice chairman of the Asian Racing Federation, chairman of the Turf Authorities of India, the Royal Western India Turf Club, the Stud Book Authority of India, and the Indian Pattern Races Committee. The pattern — diversifying into a non-core public role once the core business is built —.

Poonawalla describes the threat India's 28% betting tax — imposed under the Modi government on games of chance, including horse racing — poses to the tote, jackpots and racecourse finances. He says strong representations have been made to bring it down to the original 12% or at most 18%, with papers and presentations collected from Asian Racing Conferences showing that lower betting tax yields higher turnover, doubling or trebling revenue.

NPR opens by noting the Poonawallas — Cyrus as founder and Adar as CEO of Serum Institute — run the world's largest vaccine-producing company in the world's largest vaccine-producing nation. Serum makes vaccines for measles, tetanus, diphtheria, hepatitis and many other diseases, specializes in generic versions, exports to 170 countries, and estimates that two-thirds of the world's children are inoculated with its vaccines.

Adar Poonawalla told NPR he decided to invest tens of millions of dollars in glass vials alone and to produce four different COVID-19 vaccines — including the Oxford-AstraZeneca one — before any clinical trials proved them effective. If the vaccines worked, Serum would have hundreds of millions of doses stockpiled; if they failed, Serum would have useless vaccines and hundreds of millions of dollars in losses.

Inside Serum's sprawling Pune factory, NPR describes filled vaccine vials whizzing off conveyor belts at around 5,000 per minute. Scientists in goggles and gloves steered microscopes over a chimpanzee virus spiked with coronavirus protein. Human embryonic kidney cells fermented in floor-to-ceiling stainless steel vats imported from Europe that cost upward of $4 million each.

NPR captures the founding story: the property that houses Serum has been a stud farm since 1946, and part of it still is. The Poonawallas are a wealthy family of racehorse breeders (and collectors of luxury cars, including a Batmobile replica). In the 1960s they would donate retired racehorses to the government's Haffkine Institute, which used the horses' blood to develop serums and vaccines.

In 1966 a snake bit one of the Poonawallas' horses. The Haffkine lab had anti-venom serum but needed government permission to administer it — permission that took four days to arrive from Bombay because telephone lines were unreliable. The mare died, and the bureaucratic delay that caused her death gave Cyrus Poonawalla the idea of making the serums himself.

NPR notes Serum has partnered with the Bill & Melinda Gates Foundation and several United Nations agencies including UNICEF and the World Health Organization. By the time of the report, the company said it would ramp Oxford-AstraZeneca vaccine production to 100 million doses per month by April 2021.

The manufacturing partnership with Oxford-AstraZeneca began, NPR explains, when a tiny 1-milliliter vial arrived by courier from Oxford in May 2020 containing the components of a viral vector vaccine. Oxford supplied a weakened adenovirus that causes the common cold in chimpanzees, into which they had inserted a coronavirus protein; they also supplied cell substrate to grow the vaccine, plus technology transfer from AstraZeneca.

NPR records that by December 2020, when governments worldwide began granting emergency authorization, Serum already had hundreds of millions of doses ready to ship. The company promised half its production to the Indian government, which donated and sold supplies to about 70 countries. Serum was producing 60-70 million Oxford-AstraZeneca doses — branded as COVISHIELD —.

NPR notes a January 2021 electrical fire at Serum's Pune complex killed five people, though vaccine production was not affected. The image of black smoke billowing from the complex where Indians' best hope for COVID salvation was being produced was frightening for a watching nation. The episode illustrates how, at peak scale, operational risk at a single facility can become a national-public-health concern.

While Indian manufacturers like Serum partner with global pharmaceutical companies, NPR notes the Indian government simultaneously led a confrontation at the WTO, petitioning with South Africa to temporarily waive intellectual property protections for COVID-19 vaccines. The idea was to lift 20-year patents and let companies like Serum manufacture generic versions quickly and cheaply.